Please fax both pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form Briumvi[™] (ublituximab-xiiy)

accre 677 Ala Moana Blvd. Suite 404. lonolulu, HI 96813-5412

Four simple steps to submit your referral.

1 Patient Information		Please provide copies of front and back of all medical and prescription insurance cards.			
New patient Current patient					
Patient's first name		_ Last name		Middle initial	
Preferred patient first name		Prefe	erred patient last name		
Sex at birth: Male Female Gender	identity	Pronouns _		Last 4 digits of SSN	
Date of birth Street a	ddress			Apt #	
City	Sta	ate		Zip	
Home phone	Cell phone		Email address		
Parent/guardian (if applicable)					
Home phone	Cell phone		Email address		
Alternate caregiver/contact					
Home phone	Cell phone		Email address		
OK to leave message with alternate care	egiver/contact				
Patient's primary language: English	Other If other, please	specify			

Prescriber Information 2

All fields must be completed to expedite prescription fulfillment.

Date	Time		Date medication ne	eeded
Office/clinic/institution name				
				t name
Prescriber's title		If NP	or PA, under direc	tion of Dr
Office phone	Fax		NPI #	License #
Office contact and title			Offic	e contact email
Office street address				Suite #
City		State		Zip
				omplete information below dotted line:
Infusion info: Infusion site name _			Clinic/hospital	affiliation
Site street address				Suite #
City		State		Zip
Infusion site contact	Phon	ie	Fax	Email
Note: Check the appropriate shipr	ment options in Section	4: Prescribing I	Information.	

Clinical Information R

Primary ICD-10 code (REQUIRED):	Multiple S	clerosis: G35	Other	Laboratory results: LEVF
Hepatitis B screening date (MM/DD/	YY):	Imm	nunoglobulins	A/E/G/M quantitative screen date (MM/DD/YY):
Pregnancy test		(+/-) Date		
First two loading doses completed	Yes No	Note: Briumvi	loading doses	s must be administered in a controlled setting.
Expected date of first/next infusion _				
NKDA Known drug allergies _				
Concurrent meds				

Patient's first name	Last name	Middle initial Date of birth	
Prescriber's first name	Last name	Phone	

4 Prescribing Information

Medication	Dose	Directions	Quantity/Refills	Ship to*:
Loading Doses (two infusions) Briumvi™ (ublituximab) 150mg/6mL single-use vials	First loading dose: 150mg/6mL single-use vials are diluted in NS to a final concentration of 0.6mg/mL Second loading	First loading dose: 150mg intravenous in 250mL of 0.9% NS. Withdraw 6mL 0.9% NaCl 250mL bag and discard. Add 6mL (150mg) of Briumvi solution into the infusion bag of 0.9% NaCl. Start at 10mL per hour for the first 30 minutes. Increase to 20mL per hour for the next 30 minutes. Increase to 35mL per hour for the next hour. Increase to 100mL per hour for the remaining 2 hours. Duration: 4 hours	First loading dose: 1 vial No refills	Note: Loading doses must be administered i a controlled infusion sit Office Infusion Clinic Unknown
	dose: Use three 150mg vials for a total infusion dose of 450mg/18mL diluted in NS to a final concentration of 1.8mg/mL	Second loading dose (2 weeks later): 450mg intravenous in 250mL of 0.9% NS. Withdraw 18mL 0.9% NaCl 250mL bag and discard. Add 18mL (450mg) of Briumvi solution into the infusion bag of 0.9% NaCl. Start at 100mL per hour for the first 30 minutes. Increase to 400mL per hour for the remaining 30 minutes. Duration: 1 hour	Second loading dose: 3 vials No refills	
Maintenance Dose Briumvi™ (ublituximab) 150mg/6mL single-use vials	Use three 150mg vials for a total infusion dose of 450mg/18mL diluted in NS to a final concentration of 1.8mg/mL	Infuse 450mg intravenous in 250mL of 0.9% NaCl every 6 months (from date of the first loading dose). Withdraw 18mL from the 0.9% NaCl 250mL bag and discard. Add 18mL (450mg) of Briumvi solution into the infusion bag of 0.9% NaCl. Start at 100mL per hour for the first 30 minutes. Increase to 400mL per hour for the remaining 30 minutes. Duration: 1 hour	3 vials 1 refill	Home Office Infusion Clinic Unknown
All Briumvi [™] orders	to be administered vi	a pump and peripheral line unless otherwise instructed.		
Additional Medica	tion and Supplies f	or Home Infusion		
•		to infusion; Diphenhydramine 50mg PO 30 min prior to infusion; rior to infusion	infusion All caregivers and per protocol from	fficient for medication d ancillaries to be given n product package
Fluids for Reconstitution and Administration 0.9% NaCl 250mL 0.9% NaCl Flush 10mL (3mL pre- and post-infusion to maintain peripheral line patency.) 0.9% NaCl 50mL 0.9% NaCl 100mL			insert. (See next page.) If patient requires specific directions on additional medications or supplies, please provide change on the next page and sign.	
	ylactic reaction, stop i	nfusion of drug immediately. Start NS 15mL/hour; 0.9% NS 100mL.		
Medicate with epine physician, or parame		or 0.3mg/0.3mL IM as needed for anaphylaxis. Call *911*,		
Laughter stars are all and		quipment necessary such as needles, syringes, etc. to administer		
the therapy as need				

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN	
HERE	

Dispense as written

Date

Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



Date

_

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

Accredo Additional Medications for Home Infusion Protocol as Per Package Insert

If your patient requires individualized dosing or administering, please cross out directions below, provide desired directions in the box and sign.

Date Sigr	nature	
Medication	Dose	Directions
Diphenhydramine IV	50mg/1mL (25mg)	30 minutes prior to infusion, withdraw 0.5mL and inject into 50mL 0.9% NS. Infuse intravenously 101mL/hour over 30 min.
Diphenhydramine IV	50mg/1mL (50mg)	30 minutes prior to infusion, withdraw 1mL and inject into 50mL 0.9% NS. Infuse intravenously 102mL/hour over 30 min.
Methylprednisolone IV	100mg and Diphenhydramine PO	30 min prior to infusion, activate vial, withdraw 1.6mL/100mg, inject into 50mL 0.9% NS. Infuse intravenously 104mL/hour over 30 minutes.
Methylprednisolone IV	100mg and Diphenhydramine IV SIG	Activate vial, withdraw 1.6mL/100mg. Inject 100mg (1.6mL) intravenous push 0.2mL per minute for 8 minutes, may increase to 0.4mL per minute for 4 minutes based on absence of infusion reactions (nausea, vomiting, headache, flushing, vital sign change) 30 minutes prior to infusion.
Methylprednisolone IV	125mg SIG	30 minutes prior to infusion, activate vial, withdraw 2mL/125mg, inject into 100mL 0.9% NS. Infuse intravenously 204mL/hour over 30 minutes.
Methylprednisolone IV	250mg SIG	30 minutes prior to infusion, activate vial, withdraw 4mL/250mg, inject into 100mL 0.9% NS. Infuse intravenously 208mL/hour over 30 minutes.
Methylprednisolone IV	500mg SIG	30 min prior to infusion, activate vial, withdraw 8mL/500mg, inject into 100mL 0.9% NS. Infuse intravenously 216mL/hour over 30 minutes.
Methylprednisolone IV	125mg vial and Bacteriostatic water	Reconstitute Methylprednisolone 125mg with 2mL of Bacteriostatic water for injection. Withdraw 1.6mL/100mg.
		a. Inject 100mg (1.6mL) intravenous push 0.2mL per minute for 8 minutes, may increase to 0.4mL per minute for 4 minutes based on absence of infusion reactions (nausea, vomiting, headache, flushing, vital sign change) 30 minutes prior to infusion.
		 b. Withdraw 1.6mL and inject into 50mL 0.9% NS. Infuse intravenously 104mL/hour over 30 minutes. 30 minutes prior to infusion.
Famotidine IV	20mg	30 minutes prior to infusion, withdraw 2mL and inject into 100mL 0.9% NS. Infuse intravenously 204mL/hour over 30 minutes.
Famotidine IV	10mg	30 minutes prior to infusion, withdraw 1mL and inject into 100mL 0.9% NS. Infuse intravenously 202mL/hour over 30 minutes.

accredo.